

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics

Advances in Pharmacology

83, 65-91

DOI: [10.1016/bs.apha.2018.03.001](https://doi.org/10.1016/bs.apha.2018.03.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tumor-specific genetic profiling and therapy in biomedicine. , 2020, , 459-485.		0
2	Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1395-1404.	1.2	25
3	Role of Genetic Variations in the Hepatic Handling of Drugs. International Journal of Molecular Sciences, 2020, 21, 2884.	1.8	15
4	Improving the transparency of meta-analyses with interactive web applications. BMJ Evidence-Based Medicine, 2021, 26, 327-332.	1.7	3
5	Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology, 2021, 87, 237-255.	1.1	14
6	Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China. Pharmacogenomics Journal, 2021, 21, 60-68.	0.9	6
7	Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers, 2021, 13, 771.	1.7	26
8	Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. Journal of Personalized Medicine, 2021, 11, 507.	1.1	4
9	Antineoplastic drugs. , 2020, , 331-350.		1
10	Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 582-590.	1.1	4
11	Precision diagnostics: Integration of tissue pathology and genomics in cancer. Pathology, 2021, 53, 809-817.	0.3	2
12	Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part One. Integrative Medicine, 2021, 20, 8-15.	0.1	0
13	Pharmacogenomics of Anti-Cancer Drugs. , 2021, , .		0
14	Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer. Scientific Reports, 2022, 12, 1643.	1.6	1
15	Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells. BMC Complementary Medicine and Therapies, 2022, 22, 18.	1.2	1
16	Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry. Pharmacogenetics and Genomics, 2022, 32, 173-182.	0.7	10
17	Yeast Double Transporter Gene Deletion Library for Identification of Xenobiotic Carriers in Low or High Throughput. MBio, 2021, 12, e0322121.	1.8	5
18	Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis. Travel Medicine and Infectious Disease, 2022, 48, 102333.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Induction of ovarian steroidogenesis as an additional potential risk factor for progression in premenopausal patients with hormone-receptor-positive breast cancer receiving tamoxifen as adjuvant therapy. Meditsinskiy Sovet, 2022, , 131-138.	0.1	0
20	Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	6
21	Genetic Factors Contributing ROS-Driven Chemotherapy and Drug Resistance in Cancer. , 2022, , 3345-3361.		0
22	Genetic Factors Contributing ROS-Driven Chemotherapy and Drug Resistance in Cancer. , 2021, , 1-17.		0
23	Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study. Journal of Modern Oncology, 2022, 24, 361-367.	0.1	0
24	Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs. Discover Oncology, 2022, 13, .	0.8	3
25	Research on Clinical Effectiveness of Aspirin for Treating Breast Cancer and Cell Protein Biomarkers on Aspirin Treatment in Drug-Resistant Estrogen Receptor-Positive Breast Cancer Cells. Oncologie, 2022, 24, 743-768.	0.2	1
26	Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis. Breast, 2023, 69, 342-348.	0.9	2
27	Predictive modeling of adverse events of tamoxifen therapy for breast cancer (results of a cohort) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	0
28	Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment. Cancers, 2023, 15, 2119.	1.7	5
33	Managing the Impact of Hormone Therapy. , 2023, , 63-77.		0